Clinical Trials Sponsored by UroGen Pharma Ltd.

Total 1272 results

UroGen Pharma Ltd.

Completed

Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma

United States
UroGen Pharma Ltd.

Completed

A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer (OPTIMA II)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma

United States, Israel
UroGen Pharma Ltd.

Completed

Pre-TURBT TC-3 Gel Intravesical Instillation in NMIBC (OPTIMA)

Carcinoma of Urinary Bladder, Superficial

Israel, Spain, Italy, Switzerland
UroGen Pharma Ltd.

Completed

Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients

Neoplasms | Urologic Diseases | Urinary Bladder Diseases | Bladder Cancer

Israel
UroGen Pharma Ltd.

Terminated

Safety and Efficacy of Intravesical Botulinum Toxin in TC-3 Gel in OAB Patients

Overactive Bladder

Israel
UroGen Pharma Ltd.

Recruiting

uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto (uTRACT)

Carcinoma, Transitional Cell | Urothelial Carcinoma | Urothelial Cancer of Renal Pelvis | Urothelial Carcinoma Ureter | Urothelial Carcinoma Recurrent | Urothelial Carcinoma of the Renal Pelvis and Ureter | Urothelial Carcinoma Ureter Recurrent | Transitional Cell Carcinoma of Renal Pelvis

United States
UroGen Pharma Ltd.

Terminated

A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (ATLAS)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma

United States, Israel, Russian Federation, Georgia, Bulgaria, Estonia, Latvia, Poland, Serbia, Ukraine
UroGen Pharma Ltd.

Active, not recruiting

A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer (ENVISION)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma

United States, Spain, Lithuania, Georgia, Bulgaria, Estonia, Latvia, Poland, Serbia, Austria
UroGen Pharma Ltd.

Withdrawn

Efficacy and Safety of UGN-101 in Recurrent Patients (Retreatment)

Carcinoma | Transitional Cell Carcinoma | Transitional Cell Cancer of the Renal Pelvis and Ureter

Israel, United States
UroGen Pharma Ltd.

Withdrawn

Safety and Efficacy Study of Intravesical Instillations of BotuGelTM, Slow Release RTGel Based Botox® Formulations, in Idiopathic OAB Patients With Urinary Incontinence ("INTIMO2") (INTIMO2)

Overactive Bladder

Israel
UroGen Pharma Ltd.

Completed

Pilot Study to Evaluate the Clinical Response to Mitomycin-C in Hydrogel (TC-3) Administered Intravesically in NMIBC Patients

Neoplasms | Urologic Neoplasms | Urologic Diseases | Urinary Bladder Diseases | Urinary Bladder Neoplasms

India
UroGen Pharma Ltd.

Withdrawn

A Prospective Open Label Comparative Dose Ranging Study Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non Muscle Invasive Bladder Cancer (NMIBC) (NMIBC TURBT HG)

Non Muscle Invasive Bladder Cancer

Israel
UroGen Pharma Ltd.

Not yet recruiting

A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer (UTOPIA)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma
UroGen Pharma Ltd.

Recruiting

A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Bladder Cancer | Non-muscle Invasive Bladder Cancer | Urothelial Carcinoma Bladder | NMIBC | Urothelial Carcinoma Recurrent | Carcinoma in Situ of Bladder

United States, Italy, Spain
UroGen Pharma Ltd.

Completed

The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study (Olympus)

Carcinoma, Transitional Cell | Transitional Cell Carcinoma of Renal Pelvis

United States, Israel
UroGen Pharma Ltd.

Completed

Efficacy and Safety of Intravesical Instillations of Botulinum Toxin in TC-3 Gel in IC Patients

Interstitial Cystitis | IC

Israel
UroGen Pharma Ltd.

Completed

Safety and Tolerability Study Which Evaluate Intravesical Instillation With Mitomycin C Mixed With TC-3 Drug Retaining Hydrogel Device In Patients With Muscle Invasive Bladder Cancer

Carcinoma of Urinary Bladder, Invasive

Israel
UroGen Pharma Ltd.
Tanner Pharma Group

Available

Named Patient Program for Mitomycin for Pyelocalyceal Solution

Urothelial Carcinoma | Urothelial Cancer of Renal Pelvis | Urothelial Carcinoma Ureter | Urothelial Carcinoma Recurrent | Urothelial Carcinoma of the Renal Pelvis and Ureter | Urothelial Carcinoma Ureter Recurrent
Jonsson Comprehensive Cancer Center
UroGen Pharma Ltd.

No longer available

Compassionate Use of MitoGel in Upper Tract Urothelial Carcinoma

Urothelial Carcinoma Ureteral Location

United States
ProGen. Co., Ltd.

Recruiting

A Study to Assess Safety, Pharmacokinetics and Pharmacodynamics of PG-102(MG12) in Healthy Volunteers

Healthy | Overweight

Korea, Republic of
Uni-Pharma
Biogen

Completed

Evaluate the Efficacy and Safety of One Course of Amevive in Taiwan Patients

Chronic Plaque Psoriasis
Aerogen Pharma Limited

Active, not recruiting

A Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact

Respiratory Distress Syndrome in Premature Infant

United States, Canada
UCB Pharma
Biogen

Completed

Safety Study of CDP7657 in Patients With Systemic Lupus Erythematosus

Immune System Diseases | Autoimmune Diseases | Lupus Erythematosus, Systemic | Skin and Connective Tissue Diseases | Connective Tissue Disease

Bulgaria, Belgium, Germany, Poland, Romania, Russian Federation, Spain
UCB Pharma
Biogen

Completed

CDP323 Biomarker Study

Relapsing Multiple Sclerosis

United Kingdom
Aerogen Pharma Limited

Completed

VentaProst Versus Conventionally-Administered Aerosolized Epoprostenol in Patients Undergoing Cardiac Surgery With CPB

Pulmonary Hypertension

United States
UCB Pharma
Biogen

Terminated

Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Multiple Sclerosis

United States, France, Germany, Spain, Canada, Netherlands, Belgium, Hungary, Sweden, United Kingdom, Finland
Protgen Ltd

Completed

Phase II/III of Recombinant Human Serum Albumin

Hepatic Ascites

China
Protgen Ltd

Unknown

Clinical Trial of Quantitative Detection Kit for Hsp90α in Breast Cancer

Breast Cancer

China
Protgen Ltd

Unknown

Dose Escalation and PK Study of M2ES in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

China
AJU Pharm Co., Ltd.
OM Pharma SA

Recruiting

The Efficacy and Safety of OM-89 in Patients With Recurrent Chronic Prostatitis/Chronic Pelvic Pain Syndrome

Chronic Prostatitis With Chronic Pelvic Pain Syndrome | Chronic Prostatitis | Chronic Pelvic Pain Syndrome

Korea, Republic of
Protgen Ltd

Completed

Recombinant Human Serum Albumin in Healthy Subjects

Hepatic Ascites

China
Protgen Ltd

Unknown

Paclitaxel-Carboplatin Alone or With M2ES for Non-Small-Cell Lung Cancer

Non Small Cell Lung Cancer

China
Protgen Ltd

Completed

Recombinant Human Serum Albumin in Patients With Liver Cirrhosis and Ascites Subjects

Hepatic Ascites

China
Protgen Ltd

Unknown

Clinical Trial of Quantitative Detection Kit for Hsp90α in Hepatic Cancer

Liver Cancer

China
Protgen Ltd

Unknown

Clinical Trial of Quantitative Detection Kit for Hsp90α in Colorectal Cancer

Colorectal Cancer

China
Protgen Ltd

Unknown

Study of M2ES in Patients With Advanced Pancreatic Cancer After Gemcitabine Treatment Failure

Pancreatic Cancer

China
Protgen Ltd

Completed

Single-dose Escalation Trial of M2ES in Healthy Volunteer

Cancer
Protgen Ltd

Unknown

Study With M2ES and Gemcitabine for Patients With Advanced Pancreatic Cancer

Pancreatic Cancer

China
N4 Pharma UK Ltd.
BDD Pharma Ltd

Completed

Pharmacoscintigraphic Study to Evaluate Two Sildenafil Products

Erectile Dysfunction

United Kingdom
AtoGen Co. Ltd
ATOGEN AUSTRALIA PTY LTD

Recruiting

Safety, Tolerability, and Acceptability Study of Intravaginal Administration of LABTHERA-001 Capsules in Healthy Women

Bacterial Infections | Vaginal Disease | Vaginitis | Infection, Bacterial | Bacterial Vaginosis

Australia
Astellas Pharma Inc
Biogen

Completed

Open-label Study to Evaluate Safety of Multiple Courses of IM Alefacept During Treatment of Chronic Plaque Psoriasis

Psoriasis

Belgium, Spain, Germany, United States, France, Canada, Denmark, Netherlands, United Kingdom
Astellas Pharma Inc
Biogen

Completed

A Study to Assess the Efficacy and Safety of Two Dosing Regimens of Alefacept in Subjects Weighing Between 100kg and 150kg With Moderate to Severe Chronic Plaque Psoriasis

Chronic Plaque Psoriasis

United States, Canada
Astellas Pharma Inc
Biogen

Completed

A Placebo-controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic Arthritis

Psoriatic Arthritis

Poland, Canada, United States, Russian Federation, Germany
Astellas Pharma Inc
Biogen

Completed

Community Based Trial for AMEVIVE®

Moderate to Severe Chronic Plaque Psoriasis

United States
Astellas Pharma Inc
Biogen

Completed

A Study to Assess the Efficacy and Safety of Alefacept in Psoriasis Patients for Whom Conventional Treatment is Ineffective or Inappropriate

Chronic Plaque Psoriasis

United States, Austria, Germany, Belgium, Canada
Artios Pharma Ltd

Recruiting

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients

Advanced Solid Tumor | Metastatic Solid Tumor

United States
Elgan Pharma Ltd.

Not yet recruiting

Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants

Intestinal Malabsorption
Lutris Pharma Ltd.

Recruiting

LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC

EGFRI Induced Acneiform Lesions

United States, Israel
Artios Pharma Ltd

Active, not recruiting

A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors

Breast Cancer | Metastatic Cancer | Advanced Cancer

United States, United Kingdom
Reneo Pharma Ltd

Completed

An Efficacy and Safety Study of 24 Week Treatment With Mavodelpar (REN001) in Primary Mitochondrial Myopathy Patients (STRIDE)

Primary Mitochondrial Myopathy

United States, Spain, Australia, France, United Kingdom, New Zealand, Denmark, Norway, Czechia, Belgium, Canada, Germany, Hungary, Italy, Netherlands

Clinical Trials Sponsored by UroGen Pharma Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Greece

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations